Media Centre

May 16th 2018

Rhythm Biosciences Scores Biomarker Patents in Europe

Rhythm Biosciences (ASX:RHY) has today announced that coverage of its granted European patent (EP2829881) has been confirmed in 13 jurisdictions: Austria, Belgium, Denmark, Finland, France, Germany, Luxembourg, Netherlands, Norway, Sweden, Switzerland & Liechtenstein and the United Kingdom. These countries can now be added to the list of Australia, China and Japan, who have already granted patents to RHY for its biomarker IP towards the diagnosis of colorectal cancer. The company also has patent applications pending in the US, Brazil and India. Read more


May 14th 2018

Rhythm Biosciences’ Antibodies Pass Tests

Rhythm Biosciences (ASX: RHY), developer of the ColoSTAT blood test targeting the accurate and early detection of colorectal cancer, has completed the first phase of development of two new antibody reagents. Four independent mixed monoclonal antibody preparations have now been identified that pass all three preliminary screening tests. This work was completed under RHY’s research contract with CSIRO on time and on budget.


December 17th 2017

Cancer play Rhythm Biosciences delivers 82.5pc stag profit on ASX debut

The CSIRO’s latest spinout Rhythm Biosciences handsomely rewarded its backers on debut with an 82.5 per cent stag profit. Rhythm Biosciences (ASX:RHY), which markets a technology that promises to better detect colorectal cancer, raised $9 million issuing shares at 20c each. The shares spiked as high as 36.5c on debut Thursday — a premium of 82.5 per cent on the offer price. They closing at 32.5c — a 62.5 per cent gain for the day, valuing the company at $32.7 million. Read more


December 3rd 2017

Rhythm Biosciences Aims for ASX Listing

Healthcare veterans Shane Tanner and Lou Panaccio will be part of the board for ASX hopeful Rhythm Biosciences, which aims to commercialise a blood test to help detect early colorectal cancer. The Australian technology is potentially life-saving given colorectal cancer is the second-largest cause of cancer-related deaths in Australia, Europe and the US, and the third-largest globally. Read more

1 2 3 4 5 6